Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AZD5335 for Cancer Clinical Trial 2024 | Power
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in ...
Module 1: AZD5335 Monotherapy for Lung Adenocarcinoma Clinical Trial ...
AZD5335 for Cancer Clinical Trial 2025 | Power
AstraZeneca’s AZD5335 Study: A New Frontier in Cancer Treatment ...
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs ...
819TiP FONTANA: A phase I/IIa study of AZD5335 as monotherapy and in ...
AZD5335 and Saruparib (AZD5305) and Bevacizumab in Ovarian Cancer and ...
Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the ...
阿斯利康FRα ADC在华申报临床 8月25日，CDE官方显示， 阿斯利康 提交AZD5335的临床试验获得受理。AZD5335 是由FRα ...
【AACR 2023】ADC药物”角力”AACR-自主发布-资讯-生物在线
torvutatug samrotecan (AZD5335) / AstraZeneca
抗癌新希望:AZD5335获批临床试验,百泰派克引领ADCs分析新标准
阿斯利康FRα ADC新药AZD5335国内申报临床 - 知乎
FRα靶向的ADC-AZD5335 - 平头哥
A novel ADC, AZD5335, for the treatment of solid tumors - VJOncology
Abstract LB025: First disclosure of AZD5335, a TOP1i-ADC targeting low ...
AstraZeneca's second-generation PARP inhibitor AZD5305 is applied for ...
Abstract 815: AZD5335, a folate receptor alpha-targeted ADC, enhances ...
阿斯利康ADC布局雄心 - 知乎
抗癌新希望：AZD5335获批临床试验，百泰派克引领ADCs分析新标准_药物_抗体_癌细胞
AZD-5335(AZD-5335) - 药物靶点：FOLR1 x Top I_在研适应症：肺腺癌，晚期恶性实体瘤，卵巢癌_专利_临床_研发
AZD-5335(AZD-5335) - 药物靶点：FOLR1 x Top I_在研适应症：铂耐药上皮性卵巢癌，铂耐药性卵巢癌，实体瘤_专利 ...
AZD-5335(AZD-5335) - 药物靶点：FOLR1 x Top I_在研适应症：叶酸受体α 阳性铂类耐药的卵巢上皮癌，铂耐药上皮性 ...
AZD-5335(AZD-5335) - 药物靶点：FOLR1 x Top I_在研适应症：肺腺癌，卵巢癌，实体瘤_专利_临床_研发
1065MO First-in-human study of AZD5335, a folate receptor α (FRα ...
754P Initial results from a first-in-human study of AZD5335, a folate ...
A bifunctional molecule-based strategy for the development of ...
抗癌新希望：AZD5335获批临床试验，百泰派克引领ADCs分析新标准近日，中国国家药监局药品审评中心（CDE）官网公示 - 掘金
为现有疗法无效者破局：不挑表达、逆转耐药的ADC药物AZD5335或成潜力广谱抗癌药！医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
为现有疗法无效者破局：不挑表达、逆转耐药的ADC药物AZD5335或成潜力广谱抗癌药！ - 知乎
首款FRα ADC上市一年销量超2亿美元，FRα ADC进展如何？ - 知乎
阿斯利康FRα ADC新药AZD5335国内申报临床，针对实体瘤
FONTANA: A modular phase I/IIa, open-label, multi-center study to ...
Capability of AJICAP technology. (a) Syntheses of four different ADCs ...
How does AstraZeneca's PARP inhibitor differentiate?
阿斯利康 B7-H4 ADC 国内临床即将启动！中国研发提速中_药物_Enhertu_研究
The Landscape of Antibody-drug Conjugate (ADC): Production, Mechanisms ...
Preclinical Characterization of AZD5305, A Next-Generation, Highly ...
How Next Generation ADCs Expand Beyond Cytotoxic Payloads
Torvutatug samrotecan (AZD5335) vs mirvetuximab soravtansine gynx in ...
Frontiers | Natural killer cell therapy potentially enhances the ...
Emerging ADC Targets: B7-H3 and B7-H4
大道不孤——中国ADC创新药最新研发进展 前言 ADC， Antibody-drug Conjugate 的英文缩写，中文名称是 抗体偶联药物 ...
Trop2 ADC肺癌III期临床达PFS主要终点，浅谈Trop2 ADC研发进展|Trop2|NSCLC|ADC|PFS|DCR|乳腺癌 ...
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT ...
AZD8205（B7-H4 ADC）联合AZD5305的临床前研究 - 平头哥
AZD5305 / AstraZeneca
盛湲教授：ADC药物的狂欢—AACR T-DXd最新数据盘点-肿瘤瞭望
卵巢癌中的ADC临床疗效汇总(2026.4) - 知乎
(PDF) Payload diversification: a key step in the development of ...
首款药物Elahere上半年销售额过亿，ADC潜力靶点FRα前途可期 - 知乎
AZD-5335 - Drug Targets, Indications, Patents - Synapse
Journal of Medicinal Chemistry | Vol 65, No 17
Molecular characterization and cytotoxic effects of AZD5363, AZD8542 ...
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell ...
What Are Antibody-Drug Conjugates or ADCs? | ADC Review ADC Review
Combination of AZD5363 with doxorubicin regulates key pro‐apoptotic ...
General structure of antibody drug conjugates (ADC) and targeted ...
AZD5305 | PARP | TargetMol
.png)
